Correction to: J Clin Mov Disord 7, 2 (2020)
https://doi.org/10.1186/s40734-020-0083-0
Following publication of the original article [1], an error was identified in the Cost-per-responder sub-section.
The updated conclusion is given below and the changes have been highlighted in bold typeface.
The results showed that the adjusted mean total cost-per-responder was lower for patients receiving aboBoNT-A compared to patients receiving onaBoNT-A (€986 vs. €1524), based on the primary treatment response definition.
Reference
Misra VP, Danchenko N, Maisonobe P, et al. Economic evaluation of AbobotulinumtoxinA vs OnabotulinumtoxinA in real-life clinical management of cervical dystonia. J Clin Mov Disord. 2020;7:2 https://doi.org/10.1186/s40734-020-0083-0.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Misra, V.P., Danchenko, N., Maisonobe, P. et al. Correction to: Economic evaluation of AbobotulinumtoxinA vs OnabotulinumtoxinA in real-life clinical management of cervical dystonia. J Clin Mov Disord 7, 6 (2020). https://doi.org/10.1186/s40734-020-00088-5
Published:
DOI: https://doi.org/10.1186/s40734-020-00088-5